Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses

Christine S. Rollier a,⁎, Adrian V.S. Hill b, Arturo Reyes-Sandoval b

a Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

b The Jenner Institute, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom

Abstract

Viral-vectored vaccines are in clinical development for several infectious diseases where T-cell responses can mediate protection, and responses to sub-dominant epitopes is needed. Little is known about the influence of MVA or adenoviral vectors on the hierarchy of the dominant and sub-dominant T-cell epitopes. We investigated this aspect in mice using a malaria immunogen. Our results demonstrate that the T-cell hierarchy is influenced by the timing of analysis, rather than by the vector after a single immunization, with hierarchy changing over time. Repeated homologous immunization reduced the breadth of responses, while heterologous prime-boost induced the strongest response to the dominant epitope, albeit with only modest response to the sub-dominant epitopes.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Leading vaccine strategies aiming at inducing strong cellular immunity in humans use recombinant adenovirus (Ad) and Modified Vaccinia Ankara (MVA) [1,2]. These vectors have been assessed since the late 90s for their capacity to induce different frequency, phenotype, function and localization of T- and B-cell responses [1,3–5]. A consensus emerged that priming with Ad followed by boosting with MVA was optimal to maintain strong and long-lived CD8+ T-cell responses [5,6], and thus many comparisons have been performed in the context of various heterologous prime–boost regimens [7–9], with few exceptions comparing them individually [3,10,11]. In the latter studies, T-cell responses were measured with tetramers [3], dominant epitopes [10], or peptide pools [11], but none investigated the dominance pattern of T-cell responses induced by each vaccine vector. However, it has been suggested that the immunogenicity of the vector is likely to have a strong influence on the transgenic antigen [12]. The objective of this study was to identify the influence of Ad and MVA vaccine vectors on the hierarchy and breadth of the T-cell epitope responses to the vaccine immunogen, and to specifically address the following four questions: (1) Is the hierarchy of T cell responses influenced by the vector? (2) Does the hierarchy of T-cell responses change over time after a single immunization? (3) Do homologous or heterologous immunizations affect the T-cell hierarchy? (4) Is the hierarchy influenced by the timing between prime and boost?

2. Material and methods

2.1. Vectored vaccines

Human serotype 5 Ad and MVA vectors expressing the transgene METRAP have been described previously [13]. The insert METRAP encodes the Plasmodium falciparum TRAP and the immunodominant BALB/c H-2Kd epitope pb9 (CS252–260, SYIPSAEKI) from the P. berghei circumsporozoite protein.

2.2. Mice and immunizations

Animal experiments were performed in accordance with the U. K. Animals (Scientific Procedures) Act, 1986 and associated guidelines and EU Directive 2010/63/EU for animal experiments. Procedures were approved by the University of Oxford Animal Care and Ethical Review Committee. Groups of six 6 week-old female BALB/c mice (Harlan, UK) were injected intradermally in the ear pinna with 10⁶ pfu for MVA or 5 × 10⁹ vp for Ad, under short anesthesia using isoflurane. Ad + MVA vector mixtures (further referred as ‘Mix’) consisted of a single preparation containing both vectors at the same concentrations as each vector alone. All vaccines were injected in a final volume of 50 μl of phosphate-buffered saline.
2.3. Ex vivo IFN-γ ELISPOT and peptide targets

Peripheral mononuclear cells (PBMCs) were stimulated with peptides at a final concentration of 1 μg/ml. ELISPOT was performed as previously described [13]. Results were expressed as the average spot forming units (SFU) per million cells. Peptides included the immunodominant Pb9, Ad hexon-specific H-2Kd-restricted epitope hex486–494 KYPSPNVKIA (Kia), Ad DNA-binding protein(dbp)-specific Ld-restricted epitope dbp413–421 LPKLTPFALA (Ala), MVA epitopes previously described E3, F2G [14] and S19 [15]. Subdominant epitopes were identified in TRAP using 20mer peptides overlapping by 10 and covering TRAP aminoacid (aa) 101–310 from strain T9/96 [16]. This region was previously reported to elicit IFN-γ T-cell responses in BALB/c mice as opposed to peptides covering aa 1–110 and 301–564 (A. Spencer, personal communication and data not shown). Within this region, only epitopes 11 (IRLHSDASKNEKALIIIRS), 12 (KEKALIIIRSLSTNLQYGR), 17 (TDGIPDSIKDSLKESSRLSD), 20 (GQGINVAFNRFLVGCPSVTDG), 22 (KCYLADAVSWNQVIGPE), 25 (TASCWVDEWSPCSTCG IG) and 30 (EPLDPVDEPEDDNSPVPRPGRDN) induced detectable responses in at least 1 BALB/c mouse and are represented in the results.

3. Results and discussion

3.1. Influence of the vector and time on T-cell epitope hierarchy after a single injection

After a single injection with either Ad or MVA, or a mixture of both, T-cell responses were measured in blood at the peak of response, at week 1 for MVA and week 2 post-immunization for Ad [10], and after the contraction phase (week 10) (Fig. 1). Results are presented on a two-segment scale so that both the dominant (10,000–50,000 SFU/million cells) and subdominant (0–10,000 SFU/million cells) responses can be observed for all groups. One week after immunization, Ad induced responses only to the dominant epitope from the transgene, Pb9, while responses induced by MVA were lower but broader, targeting peptides 22, 12 and 11 in addition (Fig. 1, top panels). Responses to the vector itself also differed: MVA epitope E3 was as strong as Pb9 in the MVA-immunized group, while the Ad hexon Kia was subdominant in the Ad group. Interestingly, the mixed modality combined the advantages of both vectors: a strong Pb9 response, detectable responses to peptides 22, 11 and 12 and low responses to the MVA vector epitopes. A week later (week 2), responses to the subdominant epitopes in the transgene were detected in the Ad-immunized group (peptides 22 > 20 > 12 > 17 > 25), with higher responses but similar hierarchy as compared with MVA immunization (Fig. 1, middle panels, responses to peptides ranked 22 > 20 > 12 > 17 > 25 in the MVA-immunized group). Of note, the response to the Ad dbp epitope Ala only appeared at week 2 and became dominant over the hexon epitope Kia, reflecting the late appearance of dbp being expressed from the vector while the hexon is present on the vaccine composition [17]. Responses had contracted after 10 weeks from injection. In the MVA-vaccinated animals, viral vector epitope E3 dominated and only the transgene pb9 epitope induced a detectable response (Fig. 1, bottom panels). In contrast, the response remained dominated by Pb9 in the Ad-vaccinated animals, but the subdominant hierarchy was modified, with peptides 20 and 11 still inducing detectable responses, while the response to peptide 22 was lost.

These results suggest that the hierarchy and breadth of T-cell epitope dominance in the transgene is not influenced by the vector, but rather by the timing of analysis after immunization, and the hierarchy changes overtime, which likely reflects affinity maturation and T cell proliferation [18].

3.2. Homologous boosts influence the hierarchy of T-cell responses

To establish whether the T-cell hierarchy is modified after homologous boosting, the same vector was administered after 10 weeks. Responses were measured 1 and 2 weeks post second

---

**Fig. 1.** T-cell responses after a single injection. Groups of mice were immunized at day 0 with Ad-METRAP, or MVA-METRAP or a mix of both (Mix), as indicated on the top. IFN-γ responses were measured in individual mice 1, 2 and 10 weeks post a single injection (as indicated on the left) by ELISPOT. Results are presented as the mean and SD for each group and each peptide.
injection and 10 weeks later (weeks 11, 12 and 20, respectively) (Fig. 2). A reduction in breadth of T-cell responses was observed, focusing only on the dominant epitopes (Fig. 2): pb9 in the transgene, E3 in the MVA-MVA group, and Ad hexon Kia in the Ad-Ad and Mix-Mix groups dominant over dbp at all time points. This reflects the neutralization of the second Ad injection, resulting in lower expression of the transgene and Ad-encoded proteins (as opposed to hexon contained in the preparation) [19] (Fig. 2). The Mix-Mix modality induced a broader response that included peptides 12 in addition to 11, but responses to peptides 22, 20 and 17 were not boosted at all. The responses detected at peak were longer lived than after a single injection, as pb9 and peptide 11-specific responses were detectable at higher levels 10 weeks post boost (week 20, Fig. 2), compared to 10 weeks post prime (Fig. 1).

Therefore the timing difference between 1 week and 2 weeks post injection is not observed anymore after a homologous boost, reflecting the rapid expansion of memory T-cells rather than de novo induction [3]. The T-cell hierarchy is modified by repeated homologous immunization, with a clear narrowing and focus on dominant epitopes from the transgene or the vector. Of note, after a third homologous injection performed at week 24, Ad was completely neutralized (no boosting effect was observed as compared with week 20), and only MVA (alone or in the Mix) was able to boost the T-cell responses (Fig. 2, bottom panels), suggesting less anti-vector immunity in agreement with previous observations [13].

3.3. Effect of prime boost interval and heterologous vaccination on T-cell breadth

To assess whether narrowing of T-cell responses could be avoided with a shorter vaccination regime, we selected a 4-weeks interval shown to be suitable for eliciting T-cell response to dominant epitopes and suitable for human vaccine deployment. Groups of mice were injected at week 4 with a homologous or heterologous boost (Ad-MVA, Fig. 3). Responses were similar in both regimens (10-weeks and 4-weeks intervals) at 1 or 2 weeks post boost (comparing Fig. 2, top panels with Fig. 3, top panels). The heterologous Ad-prime MVA-boost induced the strongest response to pb9 (reaching a mean of 79,715 SFU/million cells as compared with 37,848 for Mix-Mix). Modest responses to peptides 20, 12, 11 and 22 were detectable in this group. However, when a third injection was administered 4 weeks later, at week 8, the Ad-MVA-MVA regimen also induced a narrowing of the response to pb9, with responses to peptides 11 and 12 barely detectable (measured at week 10, Fig. 3, bottom panels).

Therefore, the timing interval between prime and boost made no difference on the T-cell hierarchy and breadth. The heterologous prime-boost induced the strongest response to the dominant epitope, reflecting the expansion of memory response overcoming the induction of de novo response to the new vector. However, this regimen did not support induction of strong responses to subdominant epitopes. These results suggest that clinical selection of viral vectored-based vaccine regimen should be based on the type of
response required for protection. If a strong response to a limited number of epitope targets is required, then our results support the heterologous Ad prime – MVA boost as compared with single Ad or Mix immunization. In addition, the heterologous prime-boost was shown to improve the durability, polyfunctionality and phenotype of the T-cell response to the dominant epitope [10,13]. Results of this study reflect the difficulty to induce broad T-cell responses, important for vaccines aiming at inducing broad and long-lasting T-cell responses to variable pathogens such as HIV [20].

Conflict of interest statement
AVSH is named as co-inventor on patents related to recombinant viral vectors for malaria and other indications.

Acknowledgements
This work was funded by a Grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative of the Gates Foundation, with additional support from the Wellcome Trust. CR is supported by the NIHR Biomedical Research Centre, Oxford. CR, AVSH and AR-S are Jenner Institute Investigators, and AVSH is a Wellcome Trust and NIHR Senior Investigator. AR-S is a Wellcome Trust fellow.

CR, AR-S and AVSH conceived and designed the study, CR and AR-S conducted the experiments, acquired, analysed and interpreted the data, wrote the article, all three co-authors approved the final version of the manuscript.

The funding sources had no involvement in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

References
[1] Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011;23:377–82.
[2] Swadling L, Kleneman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther 2013;13:1109–24.
[3] Pilai VK, Kannanganat S, Penaloza-Macmaster P, Chennerardi L, Robinson HL, Blackwell J, et al. Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines. Vaccine 2011;29:5399–406.
[4] Di Nicola M, Siena S, Bregni M, Longoni P, Magni M, Milanesi M, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002;20:1039–45.
[5] Tatsis N, Lin SW, Harris-McCoy K, Garber DA, Feinberg MB, Ertl HC. Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. Virology 2007;367:156–67.
[6] Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, Nicosia A, et al. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 2010;78:145–53.
[7] Valentin A, McKinnon K, Li J, Rosati M, Kulkarni V, Pilkington GR, et al. Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clin Immunol 2014;155:91–107.
[8] Reyes-Sandoval A, Wylie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, et al. CB8+ T effector memory cells protect against liver-stage malaria. J Immunol 2011;187:1347–57.
[9] Ratto-Kim S, Currier JR, Cox JH, Excler JL, Valencia-Micolta A, Thelian D, et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS ONE 2012;7:e45840.
[10] Schirrmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 2008;16:1609–16.
[11] Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, Tang CK, et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther 2012;20:1633–47.
[14] Tscharke DC, Karupiah G, Zhou J, Palmore T, Irvine KR, Haeryfar SM, et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005;201:95–104.

[15] Oseroff C, Peters B, Pasquetto V, Moutaftsi M, Sidney J, Panchanathan V, et al. Dissociation between epitope hierarchy and immunoprevalence in CD8 responses to vaccinia virus western reserve. J Immunol 2008;180:7193–202.

[16] McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003;9:729–35.

[17] Imler JL. Adenovirus vectors as recombinant viral vaccines. Vaccine 1995;13:1143–51.

[18] Edwards LJ, Evavold BD. T cell recognition of weak ligands: roles of signaling, receptor number, and affinity. Immunol Res 2011;50:39–48.

[19] McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007;81:6594–604.

[20] Hanke T. Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines. Expert Opin Biol Ther 2014;14:601–16.